Bonefos [骨復舒] - Taiwan - 全球药品采购网

TOP

Bonefos [骨復舒]

2013-12-03 18:52:53 来源: 作者: 【大中小】浏览:1053次评论:0条

全民健康保險藥品給付規定 / 健保碼及健保價
See related Bonefos[骨復舒] information

製造商	Bayer Schering Pharma
代理/經銷商	Taicoms/Zuellig
成份	Clodronate disodium
適應症	Treatment of osteolysis due to malignancy & malignant hypercalcemia.
用量	Oral 1600 mg once daily. When higher daily doses are used, the part of the dose exceeding 1600 mg is recommended to be taken separately (as a 2nd dose). Hypercalcemia of malignancy Initially 2400-3200 mg daily, gradually decreased according to response, to a maintenance dose of 1600 mg daily. Osteolysis due to malignancy Initially 1600 mg daily, increased if necessary to a max of 3200 mg daily. IV infusion 300 mg/day diluted in 500 mL of NaCl 9% or glucose 5% soln to be administered by slow infusion over 2 hr until normocalcemia is achieved or for 5 consecutive days. Alternative: 1500 mg diluted in 500 mL vol may be given as a single dose over a 4-hr infusion.
用法	Should be taken on an empty stomach (Take w/ full glass of plain water at least 1 hr before & 2 hr after eating, drinking (except plain water) or taking other oral drugs. Swallow whole, do not chew/crush.).
禁忌	Coadministration with other bisphosphonates.
注意事項	Maintain adequate fluid intake, especially in patients on IV infusion & those with hypercalcemia or renal failure. Renal failure. Osteonecrosis of the jaw. Preventive dentistry should be considered prior to treatment w/ bisphosphonates in patients with concomitant risk factors (eg cancer, chemotherapy, radiotherapy, corticosteroids, poor dental hygiene). Avoid invasive dental procedures while patients are being treated with bisphosphonates. Pregnancy & lactation.
不良反應	Mild GI irritation, asymptomatic hypocalcemia, elevations of aminotransferases. Rarely, respiratory disorders, renal impairment. View ADR Monitoring Website[參閱藥物不良反應監測表格]
交互作用	Concomitant use with other bisphosphonates is contraindicated. Coadministration with NSAIDs may increase the risk of renal dysfunction. Use with aminoglycosides may increase the risk of hypocalcemia. May increase the serum concentration of concomitantly administered estramustine phosphate. Food or drugs containing divalent cations (e.g. antacids, Fe prep) may reduce the bioavailability of clodronate. View more drug interactions with Bonefos[骨復舒]